Acceleron Pharma Appoints Dr. Francois Nader as Chairman of its Board of Directors
06 Abril 2015 - 6:00AM
Business Wire
Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapeutic candidates that regulate
cellular growth and repair, today announced the appointment of
Francois Nader, M.D., M.B.A, as the Chairman of its Board of
Directors. Dr. Nader joined the Acceleron Board in December
2014.
“We are very pleased to appoint Dr. Nader as Chairman. His
extensive background in drug development and his success in leading
an organization through late stage development into global
commercialization in rare diseases will be an important asset for
Acceleron as we enter this exciting stage of corporate growth,”
said John Knopf, Ph.D., Chief Executive Officer of Acceleron.
Dr. Nader is a 30-year veteran of the healthcare industry. Dr.
Nader served as President, Chief Executive Officer and Director of
NPS Pharma through the recent acquisition of NPS by Shire. During
his tenure, Dr. Nader transformed NPS Pharma into a leading global
rare disease company. He joined NPS Pharma in 2006 as chief medical
and commercial officer and was promoted to chief operating officer
in 2007. Previously, he was a venture partner at Care Capital. Dr.
Nader served on the North America Leadership Team of Aventis and
its predecessor companies and held a number of executive positions
including senior vice-president, integrated healthcare markets and
North America medical and regulatory affairs. Prior to that, Dr.
Nader led the global commercial operations at the Pasteur Vaccines
division of Rhone-Poulenc. Dr. Nader currently serves as immediate
past chairman of the Board of Trustees for BioNJ, New Jersey’s
trade organization representing the biotechnology industry. He is
also a Board member of the New Jersey Chamber of Commerce, Trevena,
Inc. (TRVN) and Clementia Pharmaceuticals. Dr. Nader earned his
French Doctorate in Medicine from St. Joseph University (Lebanon)
and his Physician Executive MBA from the University of
Tennessee.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused
on the discovery, development and commercialization of novel
protein therapeutics for cancer and rare diseases. The company is a
leader in understanding the biology of the Transforming Growth
Factor-Beta (TGF-β) protein superfamily, a large and diverse group
of molecules that are key regulators in the growth and repair of
tissues throughout the human body, and in targeting these pathways
to develop important new medicines. Acceleron has built a highly
productive R&D platform that has generated innovative clinical
and preclinical protein therapeutic candidates with novel
mechanisms of action. These protein therapeutic candidates have the
potential to significantly improve clinical outcomes for patients
with cancer and rare diseases.
For more information, please visit www.acceleronpharma.com.
Acceleron Pharma Inc.Kevin F. McLaughlin, 617-649-9204Senior
Vice President and Chief Financial OfficerorMedia:Suda
Communications LLCMaureen L. Suda, 585-387-9248
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Acceleron Pharma (NASDAQ:XLRN)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024
Real-Time news about Acceleron Pharma Inc (NASDAQ): 0 recent articles
Más de Acceleron Pharma Inc. (MM) Artículos de Noticias